Inclusion Criteria:

          -  Participant must be over 18 years of age.

          -  Diagnosis of multiple myeloma with a requirement for treatment as documented per
             international myeloma working group (IMWG) criteria.

          -  Must have at least one aspect of measurable disease, defined as one of the following:

          -  Urine M-protein excretion >=200 mg/24 hours (hrs) (>=0.2 gram [g]/24 hrs), or

          -  Serum M-protein concentration >=0.5 grams per deciliter (g/dL) (>=5.0 gram per liter
             [g/L]), or

          -  Serum free light chain (FLC) assay: involved FLC level >=10 milligrams per deciliter
             (mg/dL) (>=100 milligram per liter [mg/L]) and an abnormal serum free light chain
             ratio (<0.26 or >1.65).

          -  Not a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT)
             due to presence of frailty and/or significant comorbid condition(s), such as cardiac,
             pulmonary or other major organ dysfunction that are likely to have a negative impact
             on tolerability of high dose chemotherapy with stem cell transplantation, as judged by
             the investigator.

          -  Eastern cooperative oncology group (ECOG) status of 0-2

          -  Male and/or female

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and at least 1 of the following conditions applies:

          -  Is not a woman of childbearing potential (WOCBP) or WOCBP participants must use a
             contraceptive method that is highly effective as detailed in the protocol.

          -  Male participants are eligible to participate if they agree to the following:

          -  Refrain from donating sperm

          -  Plus either:

          -  Be abstinent from heterosexual intercourse or must use a contraceptive method that is
             highly effective as detailed in the protocol.

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  Smoldering multiple myeloma (SMM).

          -  Prior systemic therapy for multiple myeloma, or SMM. An emergency course of steroids
             (defined as no greater than 40 mg of dexamethasone, or equivalent per day for a
             maximum of 4 days (that is, a total of 160 mg) is permitted.

          -  Patient is eligible for high dose chemotherapy with ASCT.

          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the
             national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE)
             Version 5.

          -  Major surgery within 4 weeks prior to the first dose of study drug.

          -  Presence of active renal condition (infection, requirement for dialysis or any other
             significant condition that could affect participant's safety). Participants with
             isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they
             fulfil criteria.

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other
             conditions (including lab abnormalities) that could interfere with participant's
             safety, obtaining informed consent or compliance to the study procedures.

          -  Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not
             explained by reversible coagulopathy.

          -  Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic
             gallstones, or otherwise stable chronic liver disease as per the Investigator's
             assessment).

          -  Participants with previous or concurrent malignancies other than multiple myeloma are
             excluded. Exceptions are surgically treated cervical carcinoma in situ, or any other
             malignancy that has been considered medically stable for at least 2 years. The
             participant must not be receiving active therapy, other than hormonal therapy for this
             disease.

          -  Evidence of cardiovascular risk.

          -  Active infection requiring treatment.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb),
             at Screening or within 3 months prior to first dose of study treatment.

          -  Positive hepatitis C antibody test result. Note: Participants with positive hepatitis
             C antibody due to prior resolved disease can be enrolled, only if a confirmatory
             negative Hepatitis C RNA test is obtained.

          -  Current corneal epithelial disease except for mild punctate keratopathy. Note:
             Participants with mild punctate keratopathy are allowed.

          -  Intolerance or contraindications to anti-viral prophylaxis.

          -  Unable to tolerate antithrombotic prophylaxis.

          -  AL amyloidosis (light chain amyloidosis), active polyneuropathy, organomegaly,
             endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS)
             syndrome or active plasma cell leukemia at the time of screening.

          -  Exhibiting clinical signs of or has a known history of meningeal or central nervous
             system involvement by multiple myeloma.

          -  Use of an investigational drug within 14 days or five half-lives (whichever is longer)
             preceding the first dose of study drug.